Effect of neoadjuvant chemotherapy in patients with triple-negative breast cancer: A meta-analysis

Tian,Muyou; Zhong,Yahua; Zhou,Fuxiang; Xie,Conghua; Zhou,Yunfeng; Liao,Zhengkai

doi:10.3892/ol.2015.3072

Effect of neoadjuvant chemotherapy in patients with triple-negative breast cancer: A meta-analysis

Authors:
- Muyou Tian
- Yahua Zhong
- Fuxiang Zhou
- Conghua Xie
- Yunfeng Zhou
- Zhengkai Liao
View Affiliations

Affiliations: Hubei Cancer Clinical Study Center, Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital, Wuhan University, Wuhan, Hubei 430071, P.R. China
Published online on: March 26, 2015 https://doi.org/10.3892/ol.2015.3072
Pages: 2825-2832

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present meta-analysis aimed to evaluate the effect of neoadjuvant chemotherapy on pathological complete response (pCR) and survival rate in patients with triple‑negative breast cancer (TNBC). Specific inclusion and exclusion criteria were used to conduct a search of the available databases, in order to find studies performed between January 2006 and January 2014. The bibliographies of the included studies were examined with the same criteria. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group framework was used to evaluate the included studies, and RevMan 5.1 and GRADEprofiler 3.6 were used to analyze the extracted data. A total of 19 studies with 6,180 patients were included. The meta‑analysis revealed that the pCR rates in patients with TNBC were significantly higher than those in patients with non‑TNBC. The 5‑year disease‑free survival (DFS) and overall survival (OS) rates were significantly lower in the patients with TNBC compared with those with non‑TNBC. Furthermore, these survival rates were significantly higher in the patients with TNBC who achieved a pCR compared with those in the patients who did not achieve a pCR. pCR rates were higher among the patients with TNBC with high Ki‑67 expression than among those with low Ki‑67 expression. The patients with TNBC exhibited lower survival rates compared with those with non‑TNBC, but achieved higher pCR rates. Moreover, those patients achieving a pCR exhibited improved 5‑year survival rates, suggesting that the pCR rate could be predictive of survival in patients with TNBC. In addition, high Ki‑67 expression may predict the likelihood of a pCR. However, future multicenter randomized controlled trials are required to enhance the quantity and quality of the clinical evidence.

View Figures

View References

1	Perou CM, Sørlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature. 406:747–752. 2000. View Article : Google Scholar : PubMed/NCBI
2	Dent R, Trudeau M, Pritchard KI, et al: Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
3	Bauer KR, Brown M, Cress RD, et al: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 109:1721–1728. 2007. View Article : Google Scholar : PubMed/NCBI
4	Charfare H, Limongelli S and Purushotham AD: Neoadjuvant chemotherapy in breast cancer. Br J Surg. 92:14–23. 2005. View Article : Google Scholar : PubMed/NCBI
5	Fisher B, Bryant J, Wolmark N, et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 16:2672–2685. 1998.PubMed/NCBI
6	Wolmark N, Wang J, Mamounas E, et al: Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 96–102. 2001. View Article : Google Scholar : PubMed/NCBI
7	Bear HD, Anderson S, Smith RE, et al: Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 24:2019–2027. 2006. View Article : Google Scholar : PubMed/NCBI
8	Heys SD, Sarkar T and Hutcheon AW: Primary docetaxel chemotherapy in patients with breast cancer: impact on response and survival. Breast Cancer Res Treat. 90:169–185. 2005. View Article : Google Scholar : PubMed/NCBI
9	Houssami N, Macaskill P, von Minckwitz G, Marinovich ML and Mamounas E: Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer. 48:3342–3354. 2012. View Article : Google Scholar : PubMed/NCBI
10	Zhou B, Xie F, Wang S and Yang D: Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triple-negative breast cancer. Zhongguo Aizheng Zazhi. 19:129–132. 2009.[(In Chinese)].
11	Kong X, Moran MS, Zhang N, et al: Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. Eur J Cancer. 47:2084–2090. 2011. View Article : Google Scholar : PubMed/NCBI
12	Li XR, Liu M, Zhang YJ, et al: CK5/6, EGFR, Ki-67, cyclin D1 and nm23-H1 protein expressions as predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients. Med Oncol. 28:(Suppl 1). S129–S134. 2011. View Article : Google Scholar : PubMed/NCBI
13	Zhang G, Xie W, Xu L, Liu Z and Xie X: Predictors of neoadjuvant chemotherapy for triple-negative breast cancer: a meta-analysis with 723 cases. Chinese-German J Clin Oncol. 12:15–19. 2013. View Article : Google Scholar
14	Livasy CA, Perou CM, Karaca G, et al: Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol. 38:197–204. 2007. View Article : Google Scholar : PubMed/NCBI
15	Sun ZK, Ma XT, Wu YD, et al: Response and Long-Term Effect of Patients with Triple-Negative Breast Cancer Receiving Neo-Adjuvant Anthracycline-Based Chemotherapy. Clin Oncol Cancer Res. 6:197–202. 2009. View Article : Google Scholar
16	Wang J and Gao R: Relationship among clinical characteristics, response and prognosis of neoadjuvant chemotherapy in patients with triple negative breast cancer. Zhong Liu Yan Jiu Yu Lin Chuang. 22:833–836. 2010.[(In Chinese)].
17	Jia H, Wu J, Li S, Gu R and Su F: Curative effects and prognostic evaluation on neoadjuvant chemotherapy of epirubicin combined with docetaxel for treating triple negative breast cancer. Ling Nan Xian Dai Lin Chuang Wai Ke. 12:261–265. 2012.[(In Chinese)].
18	Bidard FC, Matthieu MC, Chollet P, et al: p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes. Ann Oncol. 19:1261–1265. 2008. View Article : Google Scholar : PubMed/NCBI
19	Chang HR, Glaspy J, Allison MA, et al: Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment. Cancer. 116:4227–4237. 2010. View Article : Google Scholar : PubMed/NCBI
20	Darb-Esfahani S, Loibl S, Müller BM, et al: Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy. Breast Cancer Res. 11:R692009. View Article : Google Scholar : PubMed/NCBI
21	Fisher CS, Ma CX, Gillanders WE, et al: Neoadjuvant chemotherapy is associated with improved survival compared with adjuvant chemotherapy in patients with triple-negative breast cancer only after complete pathologic response. Ann Surg Oncol. 19:253–258. 2012. View Article : Google Scholar : PubMed/NCBI
22	Frasci G, Comella P, Rinaldo M, et al: Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer. Ann Oncol. 20:1185–1192. 2009. View Article : Google Scholar : PubMed/NCBI
23	Keam B, Im SA, Lee KH, et al: Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res. 13:R222011. View Article : Google Scholar : PubMed/NCBI
24	Li J, Gonzalez-Angulo AM, Allen PK, et al: Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. Oncologist. 16:1675–1683. 2011. View Article : Google Scholar : PubMed/NCBI
25	Liedtke C, Mazouni C, Hess KR, et al: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 26:1275–1281. 2008. View Article : Google Scholar : PubMed/NCBI
26	Masuda H, Masuda N, Kodama Y, et al: Predictive factors for the effectiveness of neoadjuvant chemotherapy and prognosis in triple-negative breast cancer patients. Cancer Chemother Pharmacol. 67:911–917. 2011. View Article : Google Scholar : PubMed/NCBI
27	Medioni J, Huchon C, Le Frere-Belda MA, et al: Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epirubicin for operable breast cancer: improved prognosis in triple-negative tumors. Drugs R D. 11:147–157. 2011. View Article : Google Scholar : PubMed/NCBI
28	Ono M, Tsuda H, Shimizu C, et al: Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat. 132:793–805. 2012. View Article : Google Scholar : PubMed/NCBI
29	Tang Y, Zhu L, Li Y, et al: Overexpression of epithelial growth factor receptor (EGFR) predicts better response to neo-adjuvant chemotherapy in patients with triple-negative breast cancer. J Transl Med. 10:(Suppl 1). S42012. View Article : Google Scholar : PubMed/NCBI
30	Wu J, Li S, Jia W and Su F: Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triple-negative breast cancer. J Cancer Res Clin Oncol. 137:1505–1510. 2011. View Article : Google Scholar : PubMed/NCBI
31	Yoo C, Ahn JH, Jung KH, et al: Impact of immunohistochemistry-based molecular subtype on chemosensitivity and survival in patients with breast cancer following neoadjuvant chemotherapy. J Breast Cancer. 15:203–210. 2012. View Article : Google Scholar : PubMed/NCBI
32	Smith IC, Heys SD, Hutcheon AW, et al: Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol. 20:1456–1466. 2002. View Article : Google Scholar : PubMed/NCBI
33	Sirohi B, Arnedos M, Popat S, et al: Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol. 19:1847–1852. 2008. View Article : Google Scholar : PubMed/NCBI
34	De Laurentiis M, Cianniello D, Caputo R, et al: Treatment of triple negative breast cancer (TNBC): current options and future perspectives. Cancer Treat Rev. 36:(Suppl 3). S80–S86. 2010. View Article : Google Scholar : PubMed/NCBI
35	O'Shaughnessy J, Osborne C, Pippen JE, et al: Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med. 364:205–214. 2011. View Article : Google Scholar : PubMed/NCBI